claim: baricitinib in combination with remdesivir increased time to recovery in hospitalized patients with covid-19 in niaid-sponsored actt-2 trial
evidence_1: baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir.", "study investigators noted an approximately one-day reduction in median recovery time for the overall patient population treated with baricitinib in combination with remdesivir versus those treated with remdesivir.")